An overview of triple-negative breast cancer

Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC).

(2017) M. Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.

(2017) K. A. Gelmon et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03—A multicenter, randomized phase II study.

(2017) E. Alba et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-negative breast cancer: The effect of guideline-adherent adjuvant treatment on the cumulative survival—A retrospective multicenter cohort study of 3,658 patients.

(2017) L. Schwentner et al.   JOURNAL OF CLINICAL ONCOLOGY

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

(2015) Fergus J. Couch et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression

(2014) Gilda Schmidt et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Triple-Negative Breast Cancer and the Need for New Therapeutic Targets

(2013) Olav Engebraaten et al.   AMERICAN JOURNAL OF PATHOLOGY

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

(2013) B. Gerber et al.   ANNALS OF ONCOLOGY

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer

(2013) Kristen S. Purrington et al.   CARCINOGENESIS

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC)

(2013) R. Andrés et al.   Clinical & Translational Oncology

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

Radiotherapy Can Improve the Disease-Free Survival Rate in Triple-Negative Breast Cancer Patients with T1-T2 Disease and One to Three Positive Lymph Nodes After Mastectomy

(2013) X. Chen et al.   ONCOLOGIST

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

(2013) John Stagg et al.   Therapeutic Advances in Medical Oncology

Adjuvant treatments for triple-negative breast cancers

(2012) H. Joensuu et al.   ANNALS OF ONCOLOGY

Triple-negative breast cancer in the older population

(2012) M. Aapro et al.   ANNALS OF ONCOLOGY

Imaging of triple-negative breast cancer

(2012) B. E. Dogan et al.   ANNALS OF ONCOLOGY

Vaccinia Virus GLV-1h153 Is Effective in Treating and Preventing Metastatic Triple-Negative Breast Cancer

(2012) Sepideh Gholami et al.   ANNALS OF SURGERY

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

(2012) Adam Brufsky et al.   BREAST CANCER RESEARCH AND TREATMENT

A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes

(2012) B Dutta et al.   BRITISH JOURNAL OF CANCER

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

(2012) L Robertson et al.   BRITISH JOURNAL OF CANCER

19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus

(2012) K. N. Stevens et al.   CANCER RESEARCH

Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome

(2012) Emilia Montagna et al.   Clinical Breast Cancer

Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype

(2012) Hoiseon Jeong et al.   HISTOPATHOLOGY

Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case-only study

(2012) Katharina Heusinger et al.   INTERNATIONAL JOURNAL OF CANCER

Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers?

(2012) D. Gareth Evans et al.   JOURNAL OF CLINICAL ONCOLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

(2012) Otto Metzger-Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

(2012) Harry D. Bear et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer

(2011) M. N. Fornier et al.   ANNALS OF ONCOLOGY

Breast cancer subtypes and outcome after local and regional relapse

(2011) E. Montagna et al.   ANNALS OF ONCOLOGY

Src: a potential target for the treatment of triple-negative breast cancer

(2011) D. Tryfonopoulos et al.   ANNALS OF ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

(2011) Peter A Fasching et al.   BMC CANCER

Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation

(2011) J. E. Panoff et al.   BREAST CANCER RESEARCH AND TREATMENT

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

(2011) Soley Bayraktar et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes

(2011) G. Cancello et al.   BREAST CANCER RESEARCH AND TREATMENT

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

(2011) M. Martin et al.   BREAST CANCER RESEARCH AND TREATMENT

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women

(2011) Geoffrey C. Kabat et al.   CANCER CAUSES & CONTROL

Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer

(2011) K. N. Stevens et al.   CANCER RESEARCH

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects

(2011) Ismail Jatoi et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

(2011) Donald A. Berry et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy

(2011) Bassam S. Abdulkarim et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

(2011) D. G. Evans et al.   JOURNAL OF MEDICAL GENETICS

Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer

(2011) A. I. Phipps et al.   JNCI-Journal of the National Cancer Institute

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Changing End Points in Breast-Cancer Drug Approval — The Avastin Story

(2011) Ralph B. D'Agostino   NEW ENGLAND JOURNAL OF MEDICINE

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Directed Therapy of Subtypes of Triple-Negative Breast Cancer

(2011) L. A. Carey   ONCOLOGIST

Locoregional Recurrence in Patients With Triple-Negative Breast Cancer

(2010) Anthony E. Dragun et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Multimodality Imaging of Triple Receptor–Negative Tumors With Mammography, Ultrasound, and MRI

(2010) Basak E. Dogan et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Expression of androgen receptor in breast cancer and its significance as a prognostic factor

(2010) Q. Yu et al.   ANNALS OF ONCOLOGY

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer

(2010) X. S. Chen et al.   ANNALS OF ONCOLOGY

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

(2010) Lesley A Smith et al.   BMC CANCER

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

(2010) Jens Huober et al.   BREAST CANCER RESEARCH AND TREATMENT

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

(2010) Edith A. Perez et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

(2010) Gunter von Minckwitz et al.   BREAST CANCER RESEARCH AND TREATMENT

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment

(2010) Helena R. Chang et al.   CANCER

African ancestry and higher prevalence of triple-negative breast cancer

(2010) Azadeh Stark et al.   CANCER

Triple-Negative Breast Cancer

(2010) Steven J. Isakoff   CANCER JOURNAL

Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.

(2010) L. Carey et al.   CANCER RESEARCH

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients

(2010) Marieke E. Straver et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers

(2010) Giampaolo Bianchini et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Subtypes and the Risk of Local and Regional Relapse

(2010) K. David Voduc et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic Behavior of Breast Cancer Subtypes

(2010) Hagen Kennecke et al.   JOURNAL OF CLINICAL ONCOLOGY

Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

(2010) Xiaohong R. Yang et al.   JNCI-Journal of the National Cancer Institute

Ki67 in breast cancer: prognostic and predictive potential

(2010) Rinat Yerushalmi et al.   LANCET ONCOLOGY

Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?

(2010) Catherine C. Parker et al.   SURGERY

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

(2009) B. Corkery et al.   ANNALS OF ONCOLOGY

Triple-negative breast cancer--current status and future directions

(2009) O. Gluz et al.   ANNALS OF ONCOLOGY

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

(2009) Marieke E. Straver et al.   BREAST CANCER RESEARCH AND TREATMENT

The association of metabolic syndrome with triple-negative breast cancer

(2009) B. Maiti et al.   BREAST CANCER RESEARCH AND TREATMENT

Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years

(2009) J. M. Dolle et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Androgen Receptor Inhibits Estrogen Receptor-  Activity and Is Prognostic in Breast Cancer

(2009) A. A. Peters et al.   CANCER RESEARCH

Outcome After Breast Conservation Treatment with Radiation for Women with Triple-Negative Early-Stage Invasive Breast Carcinoma

(2009) Lawrence J. Solin et al.   Clinical Breast Cancer

High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?

(2009) Yago Nieto et al.   CURRENT OPINION IN ONCOLOGY

New selective estrogen and androgen receptor modulators

(2009) Bart L Clarke et al.   CURRENT OPINION IN RHEUMATOLOGY

Triple-negative breast cancer: correlation between imaging and pathological findings

(2009) Eun Sook Ko et al.   EUROPEAN RADIOLOGY

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

(2009) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene-Expression Signatures in Breast Cancer

(2009) Christos Sotiriou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings

(2009) Takayoshi Uematsu et al.   RADIOLOGY

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

(2008) O. Gluz et al.   ANNALS OF ONCOLOGY

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

(2008) T. Byrski et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population

(2008) L. Vona-Davis et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Subtypes of Breast Cancer Show Preferential Site of Relapse

(2008) M. Smid et al.   CANCER RESEARCH

Basal Breast Cancer Molecular Subtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast Cancer

(2008) Simon J. Crabb et al.   Clinical Breast Cancer

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

(2008) M. N. Dickler et al.   CLINICAL CANCER RESEARCH

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

How basal are triple-negative breast cancers?

(2008) François Bertucci et al.   INTERNATIONAL JOURNAL OF CANCER

Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers

(2008) Yoshinari Ogawa et al.   International Journal of Clinical Oncology

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY

Basal-Like Breast Cancer: A Critical Review

(2008) Emad A. Rakha et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

(2008) Priya Rastogi et al.   JOURNAL OF CLINICAL ONCOLOGY

Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group

(2008) Marianne Kyndi et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

(2008) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Response from the Cochrane Collaboration

(2008) Mike Clarke et al.   LANCET

Insulin resistance, obesity and breast cancer risk

(2008) C. Pichard et al.   MATURITAS

Current issues in ER and HER2 testing by IHC in breast cancer

(2008) Allen M Gown   MODERN PATHOLOGY

Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors

(2008) E. Rivera et al.   ONCOLOGIST

Estrogen Receptor–Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression

(2008) Yingbing Wang et al.   RADIOLOGY

Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters

(2007) Sandip Basu et al.   CANCER

Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials

(2007) Michele De Laurentiis et al.   JOURNAL OF CLINICAL ONCOLOGY